Search clinical trials for: etigilimab

Total 3 results

M.D. Anderson Cancer Center
Mereo BioPharma

Completed

EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer

Ovarian Cancer

United States
Mereo BioPharma
ICON Clinical Research

Completed

A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.

Advanced Solid Tumor | Metastatic Solid Tumor | Solid Tumor, Adult

United States, United Kingdom
M.D. Anderson Cancer Center

Active, not recruiting

Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary Peritoneal Carcinoma | Recurrent Primary Peritoneal...

United States

3

Subscribe